Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBX-3400 in Advanced Melanoma
NCT03385486Phase 1Unknown
- Sponsor
- Taiga Biotechnologies, Inc.
- Start
- Jun 2019
- Primary completion
- Feb 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TBX-3400 in melanoma, sponsored by Taiga Biotechnologies, Inc. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 26 months. Status: unknown.
02
Drugs
TBX-3400
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03385486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385486.